GLP-1 Medications Show Promise in Reducing Stroke and Heart Risks
Recent studies highlight the cardiovascular benefits of GLP-1 medications, such as Ozempic and Mounjaro, originally designed for managing type 2 diabetes. These medications are gaining attention not only for their effectiveness in weight management but also for their potential to reduce the risks associated with heart disease and stroke.
Research published in BMJ Medicine indicates that the longer patients use GLP-1 medications, the greater the cardiovascular benefits they may experience. However, discontinuing these medications could reverse these protective effects. The study tracked over 132,000 individuals who were on GLP-1 therapy, revealing that nearly 26% stopped treatment within the first year, which raises concerns about the sustainability of heart health benefits.
At the recent SCAI 2026 Scientific Sessions in Montreal, findings were presented on GLP-1s containing tirzepatide, such as Mounjaro and Zepbound. These studies suggest that tirzepatide may significantly lower the risk of major heart issues, including stroke, by up to 30% in obese patients who have undergone heart procedures like transcatheter aortic valve replacement (TAVR). Additionally, patients with type 2 diabetes who received percutaneous coronary intervention (PCI) while on tirzepatide showed a remarkable 62% reduction in mortality compared to those treated with dulaglutide.
Cardiology experts affirm that these findings emphasize the broad cardiometabolic benefits of GLP-1 medications, suggesting they are much more than weight loss aids. Dr. Kevin Shah, a cardiologist, noted that the emerging evidence supports the notion that these drugs contribute significantly to cardiovascular health.
Moreover, GLP-1 medications are also linked to a decreased risk of thromboembolic events, such as deep vein thrombosis (DVT) and pulmonary embolism, particularly in adults with obesity and autoimmune diseases. A study published in the Journal of the American Heart Association found that GLP-1 use corresponded with a 44% reduction in overall mortality and a 31% lower risk of pulmonary embolism.
Dr. Christopher Yi, a board-certified vascular surgeon, highlighted that the anti-inflammatory properties and improvements in metabolic health associated with GLP-1 medications could explain their ability to reduce thromboembolic events. The research suggests that GLP-1 therapies might address interconnected pathways related to obesity, inflammation, and cardiometabolic dysfunction.
While the findings are promising, experts caution that more randomized trials are needed to establish the role of GLP-1 medications in preventing thromboembolic complications definitively. Nonetheless, the current evidence points to a growing understanding of how these medications can offer extensive health benefits beyond their original purpose, emphasizing the importance of continued use for long-term heart health.
